Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia

British Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2007, Pages 49-56

  Tang, Yi Lang ^a,b   Mao, Peixian ^a   Li, Feng Min ^c   Li, Wenbiao ^a   Chen, Qi ^a   Jiang, Feng ^a   Cai, Zhuo Ji ^a   Mitchell, Philip B ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Qiqi Ha'er Veterans Psychiatric Hospital   (China)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chinese race; Clozapine; Gender; Patient related variables; Plasma levels; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DRUG METABOLITE; NORCLOZAPINE; TRIHEXYPHENIDYL;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; SEX RATIO; SMOKING; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 34250631862     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02852.x     Document Type: Article

References (40)

1. Jiang Z. [Progress of atypical antipsychotics in the treatment of schizophrenia]. Chin J Psychiatry 1999 32 : 121 3 (Chinese).
2. Tang YL, Jiang ZN, Zhai YM, Wu YM. Screening and evaluation of predictive factors among refractory schizophrenics treated with clozapine [Article in Chinese]. Chin J Psychiatry 1997 30 : 157 61.
3. Tang YL. Pharmacotherapy of schizophrenia. In : Schizophrenia: from Biology to Treatments (Chinese), 1st edn, eds Cai ZJ, Weng YZ, Tang YL. Beijing : Science Press 2000 : 214 27.
4. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989 99 (Suppl. S38 40.
5. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990 147 : 1471 5.
6. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993 13 : 383 90.
7. Liu HC, Chang WH, Wei FC, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996 18 : 200 7.
8. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN. Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 1997 96 : 599 605.
9. Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol 1994 46 : 523 6.
10. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001 15 : 469 94.
11. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999 85 : 244 6.
12. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999 60 : 36 40.
13. Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol 1998 46 : 453 9.
14. Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997 44 : 447 53.
15. Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998 44 : 733 8.
16. Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano GB, Lucacchini A, Martini C, Dell'Osso L. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002 26 : 473 80.
17. Lane HY, Jann MW, Chang YC, Chiu CC, Huang MC, Lee SH, Chang WH. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001 62 : 812 7.
18. Kuss H. TDM of clozapine: influence of co-medication. In : Proceedings of VII World Conference on Clinical Pharmacology and Therapeutics; 15-20 July 2000, Florence, Italy. Oxford : Blackwell Science 2000 : 108.
19. Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry 1996 39 : 249 54.
20. Jann MW, Liu HC, Wei FC, Chang WH. Gender differences in plasma clozapine levels and its metabolites in schizophrenics patients. Hum Psychopharmacol 1997 12 : 489 95.
21. Ackenheil M, Brau H, Burkhart A, Franke A, Pacha W. [Antipsychotic efficacy in relation to plasma levels of clozapine (author's translation)]. Arzneimittelforschung 1976 26 : 1156 8.
22. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991 148 : 231 5.
23. Fabrazzo M, Esposito G, Fusco R, Maj M. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology (Berl) 1996 124 : 197 200.
24. Zhao JP, Chen YG, Chen JD, Li HD, Peng WX. Pharmacokinetic studies of clozapine: relationship of dosage and concentration and other factors [Article in Chinese]. Chin J Psychiatry 1996 29 : 220 3.
25. Peng WX, Li HD, Xu SW, Guo ZG. The effect of smoking and sex on pharmacokinetics of clozapine and norclozapine [Article in Chinese]. Chinese J Pharmacy 1997 32 : 541 4.
26. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996 153 : 820 2.
27. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th edn, DSM-IV. Washington, DC : American Psychiatric Press 1994.
28. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989 8 : 691 709.
29. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992 583 : 209 16.
30. Li WB, Qin YF, Zhai YM, Guo GX, Xu MJ. Detection of Clozapine, tricyclic antidepressants and their desmethyl metabolites in serum by high-performance liquid chromatography [Article in Chinese]. Chin J Clin Pharmacol 1999 15 : 369 73.
31. Volpicelli SA, Centorrino F, Puopolo PR, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG. Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 1993 39 : 1656 9.
32. Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit 1991 13 : 69 72.
33. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994 14 : 119 25.
34. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl) 1989 99 (Suppl. S32 7.
35. Bondesson U, Lindstrom LH. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988 95 : 472 5.
36. Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, Kane J, Lieberman J. Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry 1994 35 : 278 80.
37. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992 52 : 643 58.
38. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999 9 : 131 44.
39. Welfare MR, Aitkin M, Bassendine M, Daly A. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Pharmacogenetics 1999 9 : 367 75.
40. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004 24 : 70 8.